文献速递冠心病血脂与心血管预防

新发现的冠心病风险基因JCAD/KIAA1462促进内皮功能障碍和动脉粥样硬化

The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis.
PubMed 文献 · Eur Heart J · 2019-01-01

本研究探讨GWAS鉴定的冠心病风险基因JCAD在动脉粥样硬化中的作用机制。通过GTEx数据库分析、全局及内皮细胞特异性JCAD敲除小鼠实验、人冠状动脉内皮细胞转录组和蛋白质组研究,发现JCAD缺陷减轻高脂饮食诱导的ApoE缺陷小鼠动脉粥样硬化并改善内皮依赖性舒张,JCAD通过TRIOBP稳定应激纤维形成激活YAP/TAZ通路促进促动脉粥样硬化基因表达。结论提示JCAD促进内皮功能障碍和动脉粥样硬化,靶向JCAD可能成为冠心病治疗新策略。

要点

  • JCAD风险变异与人类动脉中JCAD表达增加相关,提示其为因果候选基因
  • 内皮细胞JCAD缺陷减轻动脉粥样硬化并改善内皮依赖性舒张
  • JCAD通过TRIOBP稳定应激纤维激活YAP/TAZ通路促进内皮功能障碍

核心结论

  • GWAS鉴定的冠心病风险基因JCAD促进内皮功能障碍和动脉粥样硬化。
  • 靶向JCAD可能成为冠心病治疗的新策略。

研究设计与样本

  • 利用GTEx数据库分析JCAD位点风险变异与基因表达的关系。
  • 构建全局和内皮细胞特异性JCAD敲除小鼠,在ApoE缺陷背景下观察高脂饮食诱导的动脉粥样硬化。
  • 对人冠状动脉内皮细胞进行全基因组转录组分析和蛋白质组研究。

主要发现

  • CAD相关风险变异与人类动脉中JCAD基因表达增加相关。
  • JCAD缺陷减轻高脂饮食诱导的ApoE缺陷小鼠动脉粥样硬化并改善内皮依赖性舒张。
  • JCAD缺失抑制人冠状动脉内皮细胞中YAP/TAZ通路激活及下游促动脉粥样硬化基因CTGF和Cyr61表达。
  • JCAD缺陷内皮细胞在LPS刺激下招募更少单核细胞。
  • JCAD在内皮细胞中的表达在体内外单向层流下降低,且在小鼠和人类动脉粥样硬化斑块中增加。

临床怎么用

  • JCAD可作为冠心病风险分层和潜在治疗靶点的候选基因。
  • 改善内皮功能障碍可能是靶向JCAD治疗冠心病的机制基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Recent genome-wide association studies (GWAS) have identified that the JCAD locus is associated with risk of coronary artery disease (CAD) and myocardial infarction (MI). However, the mechanisms whereby candidate gene JCAD confers disease risk remain unclear. We addressed whether and how JCAD affects the development of atherosclerosis, the common cause of CAD. METHODS AND RESULTS: By mining data in the Genotype-Tissue Expression (GTEx) database, we found that CAD-associated risk variants at the JCAD locus are linked to increased JCAD gene expression in human arteries, implicating JCAD as a candidate causal CAD gene. We therefore generated global and endothelial cell (EC) specific-JCAD knockout mice, and observed that JCAD deficiency attenuated high fat diet-induced atherosclerosis in ApoE-deficient mice. JCAD-deficiency in mice also improved endothelium-dependent relaxation. Genome-wide transcriptional profiling of JCAD-depleted human coronary artery ECs showed that JCAD depletion inhibited the activation of YAP/TAZ pathway, and the expression of downstream pro-atherogenic genes, including CTGF and Cyr61. As a result, JCAD-deficient ECs attracted fewer monocytes in response to lipopolysaccharide (LPS) stimulation. Moreover, JCAD expression in ECs was decreased under unidirectional laminar flow in vitro and in vivo. Proteomics studies suggest that JCAD regulates YAP/TAZ activation by interacting with actin-binding protein TRIOBP, thereby stabilizing stress fiber formation. Finally, we observed that endothelial JCAD expression was increased in mouse and human atherosclerotic plaques. CONCLUSION: The present study demonstrates that the GWAS-identified CAD risk gene JCAD promotes endothelial dysfunction and atherosclerosis, thus highlighting the possibility of new therapeutic strategies for CAD by targeting JCAD.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Xu S, Xu Y, Liu P, et al. The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis. Eur Heart J. 2019. PMID: 31539914. doi:10.1093/eurheartj/ehz303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。